Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru

PLoS Neglected Tropical Diseases

Volumn 10, Issue 2, 2016, Pages

  Forshey, Brett M ^a,i   Reiner, Robert C ^b,c   Olkowski, Sandra ^d   Morrison, Amy C ^a,d   Espinoza, Angelica ^a   Long, Kanya C ^d,e   Vilcarromero, Stalin ^a   Casanova, Wilma ^f,g   Wearing, Helen J ^h   Halsey, Eric S ^a   Kochel, Tadeusz J ^a   Scott, Thomas W ^c,d   Stoddard, Steven T ^c,d  

^a Peru   (Peru)

^b INDIANA UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ANDREWS UNIVERSITY   (United States)

^f UNIVERSIDAD NACIONAL DE LA AMAZONÍA PERUANA   (Peru)

^g Dirección Regional de Salud Loreto   (Peru)

^h UNIVERSITY OF NEW MEXICO   (United States)

ⁱ Armed Forces Health Surveillance Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CONTACT EXAMINATION; DENGUE; DENGUE VIRUS 2; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERU; PRESCHOOL CHILD; PREVALENCE; REINFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; VACCINATION; VIRUS NEUTRALIZATION; AGED; BLOOD; DENGUE VIRUS; IMMUNOLOGY; LONGITUDINAL STUDY; PROSPECTIVE STUDY; RECURRENT DISEASE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VIRUS; DISEASE OUTBREAKS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PERU; PREVALENCE; PROSPECTIVE STUDIES; RECURRENCE; YOUNG ADULT;

EID: 84959565208     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004398     Document Type: Article

References (39)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496: 504–7. doi: 10.1038/nature1206023563266
2. Holmes EC, RNA virus genomics: a world of possibilities. J Clin Invest. American Society for Clinical Investigation; 2009;119: 2488–95.
3. Sabin AB, Research on dengue during World War II. Am J Trop Med Hyg. 1952;1: 30–50. 14903434
4. Reich NG, Shrestha S, King AA, Rohani P, Lessler J, Kalayanarooj S, et al. Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc Interface. 2013;10: 20130414. doi: 10.1098/rsif.2013.041423825116
5. Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis. 2013;7: e2357. doi: 10.1371/journal.pntd.000235723951377
6. Anderson KB, Gibbons R V, Cummings DAT, Nisalak A, Green S, Libraty DH, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis. 2014;209: 360–8. doi: 10.1093/infdis/jit43623964110
7. OhAinle M, Balmaseda A, Macalalad AR, Tellez Y, Zody MC, Saborio S, et al. Dynamics of Dengue Disease Severity Determined by the Interplay Between Viral Genetics and Serotype-Specific Immunity. Sci Transl Med. 2011;3: 114ra128–114ra128. doi: 10.1126/scitranslmed.300308422190239
8. Olkowski S, Forshey BM, Morrison AC, Rocha C, Vilcarromero S, Halsey ES, et al. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis. 2013;208: 1026–33. doi: 10.1093/infdis/jit27323776195
9. Kochel TJ, Watts DM, Halstead SB, Hayes CG, Espinoza A, Felices V, et al. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet. 2002;360: 310–312. 12147378
10. Murphy BR, Whitehead SS, Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol. 2011;29: 587–619. doi: 10.1146/annurev-immunol-031210-10131521219187
11. Wahala WMPB, Silva de AM, The human antibody response to dengue virus infection. Viruses. 2011;3: 2374–95. doi: 10.3390/v312237422355444
12. Capeding MR, Tran NH, Hadinegoro SRS, Ismail HIHJM, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384: 1358–65. doi: 10.1016/S0140-6736(14)61060-625018116
13. Williams M, Mayer S V, Johnson WL, Chen R, Volkova E, Vilcarromero S, et al. Lineage II of Southeast Asian/American DENV-2 is associated with a severe dengue outbreak in the Peruvian Amazon. Am J Trop Med Hyg. 2014;91: 611–20. doi: 10.4269/ajtmh.13-060025002298
14. Cruz CD, Forshey BM, Juarez DS, Guevara C, Leguia M, Kochel TJ, et al. Molecular epidemiology of American/Asian genotype DENV-2 in Peru. Infect Genet Evol. 2013;18: 220–8. doi: 10.1016/j.meegid.2013.04.02923648427
15. DIRESA-Loreto. Situación del dengue en Loreto, al 22 de junio del 2011 [Internet]. 2012.
16. Durand Velazco S, Fiestas Solórzano V, Sihuincha Maldonado M, Chávez Lencinas C, Vásquez Vela V, Torrejón Flores C, et al. Impacto de la epidemia de dengue con un nuevo linaje del DENV-2 Genotipo Americano / Asiático en la demanda de servicios del hospital de Apoyo de Iquitos “César Garayar García”. Rev Peru Med Exp Salud Publica. 2011;28: 157–159. 21537788
17. Forshey BM, Guevara C, Laguna-Torres VA, Cespedes M, Vargas J, Gianella A, et al. Arboviral etiologies of acute febrile illnesses in Western South America, 2000–2007. PLoS Negl Trop Dis. 2010;4: e787. doi: 10.1371/journal.pntd.000078720706628
18. Watts DM, Porter KR, Putvatana P, Vasquez B, Calampa C, Hayes CG, et al. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet. 1999;354: 1431–1434. 10543670
19. Morrison AC, Minnick SL, Rocha C, Forshey BM, Stoddard ST, Getis A, et al. Epidemiology of dengue virus in Iquitos, Peru 1999 to 2005: interepidemic and epidemic patterns of transmission. PLoS Negl Trop Dis. 2010;4: e670–e670. doi: 10.1371/journal.pntd.000067020454609
20. Reiner RC, Stoddard ST, Forshey BM, King AA, Ellis AM, Lloyd AL, et al. Time-varying, serotype-specific force of infection of dengue virus. Proc Natl Acad Sci U S A. 2014;111: E2694–702. doi: 10.1073/pnas.131493311124847073
21. Stoddard ST, Forshey BM, Morrison AC, Paz-Soldan VA, Vazquez-Prokopec GM, Astete H, et al. House-to-house human movement drives dengue virus transmission. Proc Natl Acad Sci U S A. 2013;110: 994–9. doi: 10.1073/pnas.121334911023277539
22. Anderson RM, May RM, Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press; 1992.
23. Liebman KA, Stoddard ST, Morrison AC, Rocha C, Minnick S, Sihuincha M, et al. Spatial dimensions of dengue virus transmission across interepidemic and epidemic periods in Iquitos, Peru (1999–2003). PLoS Negl Trop Dis. 2012;6: e1472. doi: 10.1371/journal.pntd.000147222363822
24. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;6736: 1–9.
25. Egger JR, Coleman PG, Age and clinical dengue illness. Emerg Infect Dis. 2007;13: 924–5. 17553238
26. Kuno G, Serodiagnosis of flaviviral infections and vaccinations in humans. Adv Virus Res. 2003;61: 3–65. 14714429
27. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis. 2004;189: 990–1000. 14999601
28. Buddhari D, Aldstadt J, Endy TP, Srikiatkhachorn A, Thaisomboonsuk B, Klungthong C, et al. Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies. PLoS Negl Trop Dis. 2014;8: e3230. doi: 10.1371/journal.pntd.000323025329173
29. Cavalcanti LP, Change in Age Pattern of Persons with Dengue, Northeastern Brazil. Emerg Infect Dis. 2011;17.
30. Cologna R, Rico-Hesse R, American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol. 2003;77: 3929–38. 12634353
31. Armstrong PM, Rico-Hesse R, Efficiency of dengue serotype 2 virus strains to infect and disseminate in Aedes aegypti. Am J Trop Med Hyg. 2003;68: 539–44. 12812340
32. Anishchenko M, Bowen RA, Paessler S, Austgen L, Greene IP, Weaver SC, Venezuelan encephalitis emergence mediated by a phylogenetically predicted viral mutation. Proc Natl Acad Sci U S A. 2006;103: 4994–4999. 16549790
33. Smith KM, Nanda K, Spears CJ, Piper A, Ribeiro M, Quiles M, et al. Testing of novel dengue virus 2 vaccines in African green monkeys: safety, immunogenicity, and efficacy. Am J Trop Med Hyg. 2012;87: 743–53. doi: 10.4269/ajtmh.2012.12-000422890035
34. Bernardo L, Izquierdo A, Prado I, Rosario D, Alvarez M, Santana E, et al. Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol. 2008;15: 439–46. 18094112
35. Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al. Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. N Engl J Med. 2014; 141103114505002.
36. Sharp TM, Hunsperger E, Muñoz-Jordán JL, Margolis HS, Tomashek KM, Sequential episodes of dengue—Puerto Rico, 2005–2010. Am J Trop Med Hyg. 2014;91: 235–9. doi: 10.4269/ajtmh.13-074224891464
37. Bhoomiboonchoo P, Nisalak A, Chansatiporn N, Yoon I-K, Kalayanarooj S, Thipayamongkolgul M, et al. Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994–2010. BMC Public Health. 2015;15: 250. doi: 10.1186/s12889-015-1590-z25886528
38. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J, From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011;29: 7229–41. doi: 10.1016/j.vaccine.2011.06.09421745521
39. Halstead SB, Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine. 2013;31: 4501–7. doi: 10.1016/j.vaccine.2013.06.07923896423